TherapeuticsMD (TXMD) Free Cash Flow Growth (3y) (2013 - 2026)
TherapeuticsMD (TXMD) Free Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.42 Bn | 87.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn | 9.86% |
| 3 | Zoetis | 32.68 Bn | 30.74 Bn | 1.62 Bn | -18.92% |
| 4 | Takeda Pharmaceutical | 27.63 Bn | 23.57 Bn | 4.39 Bn | -44.64% |
| 5 | United Therapeutics | 23.16 Bn | 21.01 Bn | 648.10 Mn | 0.68% |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.34 Bn | 18.54 Bn | 1.16 Bn | -27.74% |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.47 Bn | 800.70 Mn | 46.56% |
| 9 | Elanco Animal Health | 12.65 Bn | 12.22 Bn | 785.00 Mn | 39.19% |
| 10 | TherapeuticsMD | 281,519.99 | -8.14 Mn | - | 28.23% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 28.23% |
| Dec 31, 2025 | -74.50% |
| Sep 30, 2025 | -61.65% |
| Jun 30, 2025 | 26.38% |
| Mar 31, 2025 | 26.81% |
| Dec 31, 2024 | -92.92% |
| Sep 30, 2024 | 87.70% |
| Jun 30, 2024 | 27.13% |
| Mar 31, 2024 | 81.87% |
| Dec 31, 2023 | 38.01% |
| Sep 30, 2023 | 46.19% |
| Jun 30, 2023 | 62.68% |
| Mar 31, 2023 | 39.37% |
| Dec 31, 2022 | 34.66% |
| Sep 30, 2022 | 38.40% |
| Jun 30, 2022 | 26.13% |
| Mar 31, 2022 | 22.46% |
| Dec 31, 2021 | 54.62% |
| Sep 30, 2021 | -3.83% |
| Jun 30, 2021 | -2.10% |